Replimune Group, Inc. director Veleka Peeples-Dyer filed a Form 144 notice of proposed sale on October 30, 2026, disclosing plans to sell 10,000 shares of common stock acquired through a stock option exercise on the same date.

Key Highlights

  • Proposed seller: Veleka Peeples-Dyer, listed as a Director of Replimune Group, Inc.
  • Shares proposed for sale: 10,000 shares of common stock, with an aggregate market value of $167,232.00.
  • Acquisition method: The 10,000 shares were acquired via a stock option exercise from the issuer on October 30, 2026, with cash payment on the same date.
  • Approximate sale date: October 30, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, on NASDAQ.
  • Prior sales in past 3 months: Peeples-Dyer sold 12,000 shares of common stock on October 28, 2026, with gross proceeds of $154,744.80.
  • Total shares outstanding: According to the filing, 94,800,404 shares of Replimune common stock were outstanding at the time of the notice.

Replimune Director Files Rule 144 Notice Covering Stock Option Exercise and Planned Sale

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Veleka Peeples-Dyer, a director of Replimune Group, Inc. (NASDAQ:REPL), notified the SEC on October 30, 2026, of her intent to sell 10,000 shares of the company's common stock. The filing identifies the broker as Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, with the sale to be conducted on NASDAQ.

The filing discloses that the 10,000 shares subject to the proposed sale were acquired on October 30, 2026, through a stock option exercise from the issuer, with cash payment made on the same date. The aggregate market value of the shares proposed for sale is reported as $167,232.00. The filing also notes that Peeples-Dyer's address is listed as 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801, which is the same address as the issuer.

In addition to the proposed sale, the filing requires disclosure of securities sold in the prior three months. According to the document, Peeples-Dyer sold 12,000 shares of Replimune common stock on October 28, 2026, for gross proceeds of $154,744.80. The notice was dated October 30, 2026, and signed by Veleka Peeples-Dyer. Per the filing's standard representation, the signer indicated she does not know of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.

What Was Disclosed

Replimune Group director Veleka Peeples-Dyer filed a Form 144 on October 30, 2026, covering a proposed sale of 10,000 shares valued at $167,232.00, acquired via stock option exercise, and separately reported a prior sale of 12,000 shares on October 28, 2026, for gross proceeds of $154,744.80.